Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs iShares Silver Trust — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while iShares Silver Trust trades at $54.78 (market cap $29.02B). The key difference: iShares Silver Trust is far larger — about 38× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and iShares Silver Trust for 89 Days on average.
| DNA | SLV | |
|---|---|---|
Market Cap | $763.64M | $29.02B |
Volume | 3,204,177 | 16,510,334 |
Sector | Health | — |
52-Week High | $15.83 | $105.57 |
52-Week Low | $5.48 | $42.40 |
Typical Hold Time | 7 Days | 89 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with a negative net income margin of -219.6%. Recent news includes a partnership with TuneLab and a $17.5 million ARPA-H subcontract.
The outlook is challenged by persistent losses and negative cash flow, though strategic partnerships offer growth potential. Analyst sentiment is divided evenly between buy, hold, and sell ratings. Key risks include execution on profitability and high cash burn. The stock presents a speculative opportunity dependent on the company's ability to monetize its technology platform.
SLV, the iShares Silver Trust ETF, is trading at $53.45, down 0.69% on the day, amid a bearish technical signal with 18 sell indicators versus 4 buys. The trust's assets have surged to $13.41 billion in 2024 from $10 million in 2023, though revenue and cash flows remain zero, reflecting its structure as a physical silver holding vehicle. Recent news highlights pressure from rising Treasury yields and a firming U.S. dollar, weighing on silver prices.
The outlook for SLV is heavily tied to silver's price trajectory, which faces headwinds from hawkish Fed expectations but potential support from geopolitical risks and industrial demand. Key risks include interest rate sensitivity and dollar strength, while oversold RSI levels near 26 suggest a possible near-term bounce. Investors should monitor Fed policy and macroeconomic data for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
